16.11

24.91% -5.345

Summit Therapeutics Inc (SMMT)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt SMMT? Forum Prognose

Schlusskurs vom Vortag:

$21.46

Offen:

$16.02

24-Stunden-Volumen:

18.08M

Relative Volume:

5.66

Marktkapitalisierung:

$12.51B

Einnahmen:

$220.00K

Nettoeinkommen (Verlust:

$-1.08B

KGV:

-11.15

EPS:

-1.4448

Netto-Cashflow:

$-326.53M

1W Leistung:

-27.02%

1M Leistung:

-14.83%

6M Leistung:

-14.78%

1J Leistung:

-34.68%

1-Tages-Spanne:

$15.14

$16.81

1-Wochen-Bereich:

$15.14

$22.55

52-Wochen-Spanne:

$13.83

$30.98

Summit Therapeutics Inc Stock (SMMT) Company Profile

Firmenname

Summit Therapeutics Inc

Sektor

Healthcare (1113)

Branche

Biotechnology (622)

Telefon

305-203-2034

Adresse

601 BRICKELL KEY DRIVE, MIAMI

Mitarbeiter

265

Twitter

@summitplc

Nächster Verdiensttermin

2026-05-07

Neueste SEC-Einreichungen

SMMT's Discussions on Twitter

Compare SMMT vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SMMT Summit Therapeutics Inc	16.11	12.51B	220.00K	-1.08B	-326.53M	-1.4448
VRTX Vertex Pharmaceuticals Inc	423.92	107.83B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	701.42	73.54B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	783.50	48.72B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	296.11	39.51B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	293.86	32.66B	5.36B	287.73M	924.18M	2.5229

Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-08	Eingeleitet	Stifel	Buy
2026-03-16	Herabstufung	Jefferies	Buy → Hold
2025-12-17	Hochstufung	Barclays	Underweight → Equal Weight
2025-11-18	Eingeleitet	Wolfe Research	Peer Perform
2025-09-17	Eingeleitet	Barclays	Underweight
2025-09-04	Eingeleitet	Guggenheim	Buy
2025-08-19	Eingeleitet	Piper Sandler	Neutral
2025-07-01	Eingeleitet	UBS	Buy
2025-06-11	Eingeleitet	Leerink Partners	Underperform
2025-03-26	Hochstufung	Citigroup	Neutral → Buy
2025-03-21	Eingeleitet	Cantor Fitzgerald	Overweight
2025-03-12	Eingeleitet	Evercore ISI	Outperform
2025-02-28	Eingeleitet	Goldman	Buy
2025-01-08	Eingeleitet	Truist	Buy
2024-12-11	Eingeleitet	Wells Fargo	Overweight
2024-12-06	Eingeleitet	Jefferies	Buy
2024-11-04	Eingeleitet	JMP Securities	Mkt Outperform
2024-09-27	Herabstufung	Citigroup	Buy → Neutral
2024-08-12	Eingeleitet	H.C. Wainwright	Buy
2024-05-07	Eingeleitet	Citigroup	Buy
2024-03-26	Eingeleitet	Stifel	Buy
2018-06-28	Herabstufung	Janney	Buy → Neutral
2018-05-02	Eingeleitet	Janney	Buy
2018-04-12	Bestätigt	Needham	Buy
2018-02-13	Eingeleitet	BTIG Research	Buy
2018-01-04	Eingeleitet	SunTrust	Buy
2017-12-01	Fortgesetzt	H.C. Wainwright	Buy
2016-11-16	Bestätigt	RBC Capital Mkts	Outperform
2016-10-05	Bestätigt	Needham	Buy
2016-09-16	Eingeleitet	H.C. Wainwright	Buy
2015-03-30	Eingeleitet	Needham	Buy
2015-03-30	Eingeleitet	Oppenheimer	Outperform

Alle ansehen

Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten

May 01, 2026

Summit Therapeutics Inc. Q1 2026 Financial Results: Forward-Looking Statements, Clinical Trial Updates, and Segment Reporting - Minichart

May 01, 2026

SMMT Stock Plunges On Wider Q1 Loss, Lung Cancer Clinical Trial Update - Stocktwits

May 01, 2026

Summit Therapeutics Shock Move Hits Nasdaq Futures - Kalkine Media

May 01, 2026

Merck's Biggest Looming Rival In Cancer Just Took A Gut Punch - Investor's Business Daily

May 01, 2026

U.S. Markets Closed Mixed Friday As Pershing Square Led, Summit Therapeutics Lagged - Barron's

May 01, 2026

Summit Therapeutics Shares Fall After 1Q Loss Widens - Moomoo

May 01, 2026

Summit Therapeutics Stock Plunges 23%: The Ivonescimab Update Shaking Its Keytruda Challenge - TechStock²

May 01, 2026

Stock Market Today: Apple Earnings Power S&P 500, Nasdaq To Records; Trump Hits EU - Benzinga

May 01, 2026

Summit Therapeutics (SMMT) Sees Significant Drop in Stock Price - GuruFocus

May 01, 2026

How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III - BioWorld News

May 01, 2026

Evercore Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $34 - Moomoo

May 01, 2026

Summit Therapeutics Stock Dips After Q1 Financial Report - Benzinga

May 01, 2026

Goldman Sachs Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $41 - Moomoo

May 01, 2026

Summit Therapeutics (SMMT) slides 24.7% as investors digest Q1 loss and an interim trial update that didn’t deliver an early efficacy win - Quiver Quantitative

May 01, 2026

Summit Therapeutics stock falls after Q1 update (SMMT:NASDAQ) - Seeking Alpha

May 01, 2026

Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal - Yahoo Finance

May 01, 2026

Summit Therapeutics PLC $SMMT Shares Sold by Pictet Asset Management Holding SA - MarketBeat

May 01, 2026

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026 - BioSpace

May 01, 2026

Apr 30, 2026

Clear Street Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Cuts Target Price to $31 - Moomoo

Apr 30, 2026

Impressive Progress for SMMT with New Bispecific Antibody Develo - GuruFocus

Apr 30, 2026

Summit Therapeutics (SMMT) Reports Q1 EPS Beat with Strong Cash Position - GuruFocus

Apr 30, 2026

Is Summit Therapeutics (SMMT) Attractive After Q1 2026? EPS $(0. - GuruFocus

Apr 30, 2026

Press Release: Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026 - 富途牛牛

Apr 30, 2026

Summit Therapeutics (NASDAQ: SMMT) posts larger Q1 loss amid cash burn and trials - Stock Titan

Apr 30, 2026

Earnings Flash (SMMT) Summit Therapeutics Inc. Posts Q1 Adjusted Loss $0.15 per Share, vs. FactSet Est of $-0.17 - marketscreener.com

Apr 30, 2026

Summit Therapeutics PLC (Nasdaq: SMMT) recently disclosed its financial report and business development updates for the first quarter ending March 31, 2026. - Bitget

Apr 30, 2026

Summit Therapeutics (NASDAQ: SMMT) ramps ivonescimab trials, widens Q1 2026 net loss - Stock Titan

Apr 30, 2026

Summit Therapeutics: It Still Feels Like The Market Got Ahead Of Itself (NASDAQ:SMMT) - Seeking Alpha

Apr 30, 2026

Summit Therapeutics (SMMT) Expected to Announce Earnings on Thursday - MarketBeat

Apr 30, 2026

Apr 28, 2026

Summit Therapeutics (SMMT) Leads Healthcare Stocks with 372.66% CapEx Growth - GuruFocus

Apr 28, 2026

Summit Therapeutics leads all large-cap healthcare stocks in YoY CapEx growth (XLV:NYSEARCA) - Seeking Alpha

Apr 28, 2026

Apr 27, 2026

Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $45 - Moomoo

Apr 27, 2026